Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 17/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 9/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873739 | 0.89 | MAPK1 (0.48) | MAPK1MAPK3PIK3C3CDC7DBF4 | |
| SCHEMBL19350397 | 0.81 | MAPK1 (0.56) | MAPK1MAPK3PIK3C3CDC7DBF4 | |
| SCHEMBL17873706 | 0.80 | MAPK1 (0.55) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL17873707 | 0.80 | CDC7 (0.35) | CDC7DBF4 | |
| SCHEMBL19373783 | 0.79 | MAPK1 (0.53) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL19350400 | 0.78 | MAPK1 (0.53) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL19350393 | 0.78 | MAPK1 (0.51) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL19350405 | 0.78 | MAPK1 (0.51) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL19383016 | 0.78 | MAPK1 (0.53) | MAPK1MAPK3PIK3C3MAPK6 | |
| SCHEMBL19350390 | 0.78 | MAPK1 (0.51) | MAPK1MAPK3PIK3C3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237420-B1 | ERK INHIBITORS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3237420-A1 | ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267691-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK1 2/4885MAPK3 3/4885PIK3C3 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.